Development of a high-throughput ELISA assay for platelet function testing using platelet-rich plasma or whole blood

Summary

Platelets play an essential role in the development of cardiovascular diseases and are the target of several agents that can inhibit their function. Despite the existence of a wide array of techniques to study platelet function, an assay to evaluate several platelet signalling pathways in a high-throughput fashion, combined with minimal blood volume and handling is still needed. We have developed a sensitive assay in the form of a sandwich ELISA where monoclonal antibodies against P-selectin or αIIbβ3 and GPIbα were used to capture and detect platelets, respectively, in the presence of five different agonists [ADP, TRAP (thrombin receptor agonist), U46619 (thromboxane A2 analogue), collagen-related-peptide, and arachidonic acid]. Binding of platelets to the antibodies increased dose-dependently with the concentration of either agonist, while binding of ADP-activated platelets was abrogated when inhibitors of platelet activation were concomitantly added. The test showed good sample reproducibility in 15 healthy donors with conserved platelet response to agonists throughout the assay. Healthy subjects could be identified as normal-, hypo- or hyper-responders for each agonist, which for most cases (73%) was confirmed upon retesting. Finally, we demonstrated that the platelet ELISA assay can not only be used in platelet-rich plasma but also in whole blood; it now awaits large scale studies to assess its full screening and diagnostic values.

Keywords

Platelet function tests - platelet ELISA - platelet activation

• References

• 1 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
• 2 Lecut C, Schoolmeester A, Kuijpers MJ. et al. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24: 1727-1733.
• 3 Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
• 4 Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 01: 1602-1612.
• 5 Deckmyn H, Vanhoorelbeke K, Ulrichts H. et al. Amplification loops and signal transduction pathways. eds. Leuven University Press. 2003: 75-91.
• 6 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 03: 1800-1814.
• 7 Deckmyn H, Ulrichts H, Van De Walle G. et al. Platelet antigens and their function. Vox Sanguinis 2004; 87 (Suppl. 02) 105-111.
• 8 Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171-191.
• 9 Mitchell JA, Ali F, Bailey L. et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008; 93: 141-147.
• 10 Jones CI, Garner SF, Angenent W. et al. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007; 05: 1756-1765.
• 11 Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Sem Thromb Hemost 2005; 31: 393-399.
• 12 Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005; 10: 177-181.
• 13 Zwierzina WD, Kunz F. A method of testing platelet aggregation in native whole blood. Thromb Res 1985; 38: 91-100.
• 14 Shah U, Ma AD. Tests of platelet function. Curr Opin Hematol 2007; 14: 432-437.
• 15 Moran N, Kiernan A, Dunne E. et al. Monitoring modulators of platelet aggregation in a microtiter plate assay. Analyt Biochem 2006; 357: 77-84.
• 16 Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103 (Suppl. 03) 20A-26A.
• 17 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 18 Peace AJ, Tedesco AF, Foley DP. et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 06: 2027-2034.
• 19 Cauwenberghs N, Vanhoorelbeke K, Vauterin S. et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-660.
• 20 Wu G, Xi X, Li P. et al. Preparation of a monoclonal antibody, SZ-51, that recognizes an alpha-granule membrane protein (GMP-140) on the surface of activated human platelets. Nouv Rev Franc Hematol 1990; 32: 231-235.
• 21 Deckmyn H, Stanssens P, Hoet B. et al. An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. Br J Haematol 1994; 87: 562-571.
• 22 Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-268.
• 23 Stenberg PE, McEver RP, Shuman MA. et al. A platelet alphagranule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
• 24 Chung AW, Jurasz P, Hollenberg MD. et al. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 2002; 135: 1123-1132.
• 25 Cauwenberghs N, Meiring M, Vauterin S. et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscl Thromb Vasc Biol 2000; 20: 1347-1353.
• 26 Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coag Fibrinol 1994; 05: 97-119.
• 27 Milet-Marsal S, Breillat C, Peyruchaud O. et al. Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 655-662.
• 28 Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95: 75-82.
• 29 Dropinski J, Jakiela B, Sanak M. et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Hae-most 2007; 98: 201-209.
• 30 Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leuko-cyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
• 31 Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-1947.
• 32 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
• 33 Metzelaar MJ, Korteweg J, Sixma JJ. et al. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993; 121: 579-587.
• 34 Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
• 35 Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007; 33: 273-282.
• 36 Gibbs NM. Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care 2009; 37: 354-369.
• 37 Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
• 38 Chandler AB, Earhart AD, Speich HE. et al. Regulation of CD40L (CD154) and CD62P (p-selectin) Surface Expression upon GPIIb-IIIa Blockade of Platelets from Stable Coronary Artery Disease Patients. Thromb Res 2010; 125: 44-52.
• 39 Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20: 250-259.
• 40 Blais N, Pharand C, Lordkipanidze M. et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydro-thromboxane B(2). Thromb Haemost 2009; 102: 404-411.
• 41 McKenzie ME, Malinin AI, Bell CR. et al. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis 2003; 14: 249-253.
• 42 Hubl W, Assadian A, Lax J. et al. Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry. Thromb Res 2007; 121: 135-143.
• 43 Panzer S, Hocker L, Koren D. Agonists-induced platelet activation varies considerably in healthy male individuals: studies by flow cytometry. Ann Hematol 2006; 85: 121-125.
• 44 Schmitz G, Rothe G, Ruf A. et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-896.
• 45 Feijge MA, van Pampus EC, Lacabaratz-Porret C. et al. Inter-individual variability in Ca2+ signalling in platelets from healthy volunteers: effects of aspirin and relationship with expression of endomembrane Ca2+-ATPases. Br J Haematol 1998; 102: 850-859.
• 46 Walters J, Skene D, Hampton SM, Ferns GA. Biological rhythms, endothelial health and cardiovascular disease. Med Sci Monitor 2003; 09: RA1-8.
• 47 Peace AJ, Egan K, Kavanagh GF. et al. Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. J Thromb Haemost 2009; 07: 1941-1943.